Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments
© Ngorsuraches and Thongkeaw. 2015
Received: 25 March 2015
Accepted: 28 October 2015
Published: 5 November 2015
Patients’ preferences increasingly play roles in cancer treatments. The objective of this study is to examine breast cancer patients’ preferences and willingness-to-pay (WTP) for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments. Four attributes, i.e. progression free survival (PFS), anemia, pneumonitis, and cost, and their levels of exemestane and exemestane plus everolimus from literature and patient interviews were used to develop a discrete choice experiment questionnaire. Each questionnaire was composed of seven choice sets and each choice set contained those four attributes with different levels. Breast cancer patients were asked to choose one treatment alternative in each choice set. Multinomial logit model was used to determine relative preferences of each attribute and the WTP for all attributes and treatments were calculated. A total of 146 patients were included in study analyses. Results showed that the patients preferred treatments with higher PFS and lower side effects. The patients were willing to pay US$151.6, US$69.8, and US$278.3 per month in exchange for every 1 month increase in PFS and every 1 % decreased risk of anemia and pneumonitis, respectively. The patients were willing to pay for exemestane and exemestane plus everolimus US$551.8 and US$414.2 per month, respectively. In conclusion, patients weighted importance on PFS, anemia, and pneumonitis, when they needed to choose an aromatase inhibitor plus mammalian target of rapamycin (mTOR) inhibitor for advanced breast cancer treatments after failure of standard treatments. They valued exemestane alone more than exemestane plus everolimus.
Breast cancer is the most common cancer in women worldwide. In 2012, globally the incidence rate and mortality rate of breast cancer was 38.9 and 13.0 per 100,000 (Ferlay et al. 2013). In Thailand, while the incidence rate was relatively lower (22.4 per 100,000), the mortality rate was slightly higher (13.8 per 100,000) (Ferlay et al. 2013). The 5-year prevalence was 54,269 cases in the country (Ferlay et al. 2013). Among all breast cancer patients in Thailand, metastatic breast cancer accounted for 8.8 %, which tended to require advance and costly therapy (National Cancer Institute, Thailand 2011).
Immunohistochemistry has advanced breast cancer prognosis and treatments by identifying hormone receptor (HR) oestrogen receptor (ER) and/or progesterone (PR) and human epidermal growth factor receptor HER2 pathways (Park et al. 2012; Dedes et al. 2011). Based on these receptor pathways, breast cancers are classified into four subtypes—luminal A (ER+ and/or PR+, HER2−, Ki-67 < 14 %), luminal B (ER+ and/or PR+, HER2−, Ki-67 ≥ 14 % or ER+ and/or PR+, HR2+), HER2-enriched (ER−, PR−, HER2+), and triple-negative breast cancer (TNBC) (ER−, PR−, HER2−). They accounted for 59.3, 12.3, 13.3, and 15.1 % of Thai women, respectively (Chuthapisith et al. 2012). The use of treatments targeting the ER and HER2 in patients with early-stage breast cancer has resulted in noticeable reductions in tumor recurrence and death, but resistance to these treatments often due to the activation of alternative survival pathways can develop and cause disease progression (Dhillon 2013). These pathways have been a focus for the development of new anticancer treatments.
Among those pathways, the phosphatidylinositol 3-kinases (PI3 K)/Akt/mammalian target of rapamycin (mTOR) pathway plays an important role in breast cancer cell proliferation and cancer treatment resistance (Dhillon 2013). The inhibitor of mTOR was shown to restore breast cancer cells’ sensitivity to hormone. An mTOR inhibitor, everolimus, has become a promising treatment for several types of tumors (Dhillon 2013). Everolimus was first approved only for patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib or vascular endothelial growth factor (VEGF) targeted therapy in several countries as same as in Thailand (Dhillon 2013; Baselga et al. 2012; Bachelot et al. 2014). In 2012, it was approved in the US for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of standard treatments, e.g. letrozole or anastrozole (National Cancer Institute 2013). In 2013, the Breast cancer trials of OraL Everolimus-2 (BOLERO-2) data showed the results from final progression-free survival (PFS) analysis of everolimus used in patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer (Yardley et al. 2013). The addition of everolimus to exemestane significantly prolonged median PFS, as compared to exemestane alone (7.8 vs 3.2 months by local investigators and 11.0 vs 4.1 months by central assessment). After final 18-month follow-up, the percentage of overall survival (OS) events of everolimus plus exemestane was 25.4 % while the OS of exemestane alone was 32.2 %. While the most commonly reported adverse events of the everolimus plus exemestane included stomatitis, rash, fatigue, diarrhea, nausea, decreased appetite, weight loss, and cough, the most common grade 3 and 4 adverse events were stomatitis, fatigue, dyspnea, anemia, hyperglycemia, and gammaglutamyltransferase increase.
While the technology of cancer treatments has been moving forward and available at high costs, countries need to manage healthcare budgets efficiently. Thailand is not different from other countries and it needs even more resources since it also has provided universal health coverage to every citizen. Even though the data of public health expenditure on cancer did not exist, there were two examples showing that the country has focused heavily on cancer treatments and had a difficulty to ensure access to the treatments. First, in 2008, Thailand needed to grant compulsory licenses for four drugs, which also included letrozole and docetaxel for breast cancer. Even though the public positively viewed this policy and its benefits, it was a contentious decision (Chalkidou et al. 2014). Another example was that the country has used health technology assessment (HTA) as a decision making tool for allocating resources efficiently and it had immense influence on cancer preventions, treatments, and consequences in the country (Chalkidou et al. 2014). One of study results, specifically related to breast cancer, showed that once-in-a-lifetime population-based mammographic screening for women aged either 40−49 or 50−59 years did not have a good value in Thailand (Chalkidou et al. 2014). Historically, while Thai government and pharmaceutical industry had debated between treatment benefits and costs of cancer treatments, patients were rarely involved. As taxpayers, patients should be able to share their decisions. More attention should be given to patients’ preferences for treatment options, especially new and costly treatments. Also, if the government decided not to cover those innovative cancer treatments, patients would assume very high cost burden. The objective of this study was therefore to understand how patients’ preferences for characteristics of postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole and to estimate their willingness-to-pay (WTP) by using a discrete choice experiment (DCE). Specifically, exemestane plus everolimus was used as a case study.
Patients’ characteristics (N = 146)
Age (years, mean ± SD)
53.2 ± 10.2
Marital status [N (%)]
96 (65.8 %)
50 (34.2 %)
Educational level [N (%)]
97 (66.4 %)
Secondary school/high school/diploma
40 (27.4 %)
College/university or higher
9 (6.2 %)
Occupation [N (%)]
3 (2.1 %)
32 (21.9 %)
84 (57.5 %)
27 (18.5 %)
Monthly income (US$, mean ± SD)
355.2 ± 2253.7
Health insurance [N (%)]
113 (77.4 %)
Civil servant medical benefit scheme
13 (8.9 %)
20 (13.7 %)
Perceived current health status [N (%)]
4 (2.7 %)
55 (37.7 %)
77 (52.7 %)
10 (6.8 %)
Average years of breast cancer diagnosed (years, mean ± SD)
3.0 ± 3.1
Current breast cancer treatment [N (%)]
1 (0.7 %)
18 (12.3 %)
68 (46.6 %)
No treatment at the time being
47 (32.2 %)
Do not know
11 (8.2 %)
Estimated parameters of multinomial logit model
Progression free survival
Cost per month
−0.32169 × 10−4
0.16383 × 10−5
Patients’ willingness-to-pay per month for one level change of each attribute (US$)
Progression free survival
95 % confidence interval
To our best knowledge, this was one of very few studies to elicit breast cancer patients’ preferences on their treatments using DCE. Recently, there have been emerging breast cancer treatments with some certain risks, especially adverse events. The results of this study could help clinicians choose the treatments, based on patients’ preferences of both clinical outcomes and economic burden.
This study intended to examine patients’ preferences for attributes of postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole and to estimate their WTP for the treatments. Interestingly, when patients learned about the benefits and risks of the treatment options that they had—aromatase inhibitor vs aromatase inhibitor plus mTOR inhibitor—for this type of breast cancer after failure of standard treatments, they tended to agree what attributes were important to them. We could conclude within interviewing only six patients. Among various benefits, patients focused more on PFS than on clinical benefit rate and on overall survival (compared to placebo). These results were consistent with medical literature, which considered PFS as the primary outcome for these treatments. Interestingly, among several kinds of adverse events, patients prioritized anemia and pneumonitis, which were two most common grade 3 or 4 adverse events from aromatase inhibitor plus mTOR inhibitor (Dhillon 2013). A reason could be that when they imagined they already suffered so much from having advanced breast cancer and they probably did not want any additional disease or symptom that could worsen their health. Also, among the adverse events they learned, anemia and pneumonitis would possibly sound more severe than others, e.g. stomatitis, hyperglycemia, etc.
The study results suggested that patients had different preferences for the attributes of postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole. They were willing to trade among these attributes when they needed to choose the treatments. The results were intuitive that patients preferred higher treatment efficacy (PFS), lower adverse events (anemia and pneumonia or pneumonitis), and lower cost. Based on the same unit of measurement in the DCE, apparently patients weighed more on pneumonitis than on anemia. One of the reasons could be that they could have heard about or had experience or knew someone who had pneumonitis in the past, while anemia was generally rare and probably harder for the patients to perceive its consequences. On the other hand, we could not directly compare the importance between PFS and the adverse event due to their different units of measurement. However, from the ratios of their estimated parameters, we found that the maximum levels of anemia and pneumonitis, which patients were willing to accept in order to increase one month of PFS, were approximately 2 and 0.5 %, respectively. In other words, patients could accept higher risk for anemia to trade for PFS. Our results were inconsistent with the results from an only previous DCE study on breast cancer patients’ preference for prophylactic granulocyte colony-stimulating factors (Johnson et al. 2014). Even though they might not be a good comparison due to various differences, e.g. populations, it was worth noting that the patients in that study weighed treatment effects on blood cells (neutropenia) more than on infection while our patients cared treatment effects on inflammation (pneumonitis) than on blood cells (anemia). An explanation could be that patients might have different preferences on treatment and prophylaxis. For prophylaxis, patients might concern more on neutropenia because it could be a major disruption for their main treatment. On the other hand, for treatment, patients might consider that it was their main treatment and they should focus more on the adverse event that they have been familiar with.
The results indicated that while patients would like to have longer PFS, they had more concern on pneumonitis, which they might have from using the exemestane plus everolimus instead of exemestane alone. Even though the patients in this study had relatively low monthly incomes, they were willing to pay about a half of all their average monthly income to trade for a month of PFS. Unfortunately, the small sample size in this study did not allow us to examine the association between income and WTP. Since the patients’ WTP for not having both anemia and pneumonitis were high, these amounts finally made them willing to pay monthly for exemestane plus everolimus lower than for exemestane alone. Interestingly, while the WTP for exemestane alone calculated from this study was almost four times higher than its cost (US$140.2), the WTP for exemestane plus everolimus was extremely lower than its cost (US$4712.1) in Thailand. These costs were obtained and estimated from the (Ministry of Public Health 2013). Recently the estimated monthly costs for exemestane and exemestane plus everolimus from the same source declined to US$102.1 and US$2874.3, respectively. Ones could argue that WTP may not be a good estimation for market price. However, as a simple cost-benefit analysis, the interpretation of the results should be that the patients valued the benefits for exemestane more than its cost, but they valued the benefits for exemestane plus everolimus much less than its cost. In other words, they realized net costs of exemestane plus everolimus, which meant it was not worth their value of money in case they had advanced breast cancer treatments after failure of standard treatments. One of the reasons that the patients might perceive that everolimus cost them more than its additional benefits to exemestane could be that the additional PFS from adding everolimus was only approximately 7 months, which were relatively short, as compared to other additional risks that patients could have during those months. It was worth mentioning here that the majority of these patients were under universal health coverage scheme sponsored by Thai government. It could be a reason that their WTP were low.
This study suffered from various limitations. First, even though DCE used in this study is a state-of-the-art stated preference method, ones may always argue that it does not reveal or reflect true preference or value since all decisions are not really made. However, this study already tried to minimize validity threats as many as possible, e.g. providing an opt-out alternative in each choice set, which resembled real-life choices. Second, all choice sets comprised only limited number of treatment attributes. There were other attributes that could also affect patients’ preferences. Further research should examine more attributes, which might provide better understandings of patients’ preferences and their WTP. However, the patient interviews would reassure that this limitation should be negligible. Third, since it was not possible to include only patients, who had postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole, patients in this study could be at any stage of breast cancer. They might not be good representatives for this specific type and stage of breast cancer. However, as stated in the methods, we described the disease condition to ensure that they could imagine well while they were making decisions. Finally, this study examined preferences among patients from only one hospital in southern Thailand, the results could not be generalized to patients in other settings since they might have different socioeconomic characteristics, especially income and education levels, which could affect patients’ preferences and WTP.
In conclusion, this study revealed that patients weighted importance on PFS, anemia, and pneumonitis, when they needed to choose an aromatase inhibitor plus mTOR inhibitor for advanced breast cancer treatments after failure of standard treatments. Specifically, they valued net benefits for exemestane, but not for exemestane plus everolimus. Also, they were willing to pay more for exemestane alone than for exemestane plus everolimus.
Patients and methods
DCE has been used to measure the preferences of respondents for various treatment alternatives from well-designed choice sets in the healthcare field. This study followed a user’s guide for DCE published by Lancsar and Louviere (Lancsar and Louviere 2008). In general, DCE describes various choice sets of a treatment by its attributes, e.g. efficacy, side effects, and costs. Each choice set contains various hypothetical alternatives with different attributes and levels, randomly combined by a rigorous method of DCE study design. Respondents are asked to choose one alternative that they prefer from each choice set. Finally, statistical analysis based on Random Utility Theory is used to determine the influences of attributes on respondent preference.
Attributes and levels
Attributes and levels of treatments for patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole
Progression free survival (PFS)
2, 8, 14 months
0, 3, 6 %
0, 2, 4 %
0, US$3030.3, US$6060.6a
Discrete choice experiment questionnaire design
This study conveniently sampled breast cancer patients, who visited the outpatient surgery department of a tertiary care hospital during May to September 2013 and aged 18 years old or above. Since the number of patients, who had postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of treatment with letrozole or anastrozole, were small, it was not possible to select only them in the study. Breast cancer patients at any stage were included. However, they must experience surgery, radiotherapy, chemotherapy, hormonal therapy, or other cancer treatments, and had been in the follow-up period for at least 3 months in order to ensure that they had some experiences with cancer treatments. Since the choice sets used in this study were unlabeled choices, there was no sample size calculation formula (de Bekker-Grob et al. 2010). This study followed the suggestion from Rose and Bliemer for continually collecting data until all criteria were found statistically significant (Rose and Bliemer 2013). The ethics committee of the hospital, where patients were recruited, approved the study proposal. We explained all study details to patients. If they agreed to participate to the study, they needed to sign an informed consent.
Before we interviewed the patients by using the designed questionnaires, we briefly described and ensured that they understood about advanced breast cancer, its treatments, and side effects. We asked patients to imagine if patient were in the situation that had already had the standard treatments for advanced breast cancer and the treatments failed, then they were asked to choose two treatment alternatives and an opt-out alternative in each choice set. An example of a completed choice set was provided. Each respondent received only one questionnaire, which contained a total of seven choice sets.
Marginal WTP of the attributes were calculated by taking the ratio of the mean attribute coefficient to the mean coefficient of cost attribute. Each of them represented how much one was willing to pay for a 1-unit change in the attribute. Krinsky and Robb method was used to estimate 95 % confidence intervals of WTPs of the attributes (Krinsky and Robb 1986). Finally, we calculated WTP for both exemestane and exemestane plus everolimus by multiplying the marginal WTP for each particular treatment’s attribute and its level changes, which were obtained from literature (Baselga et al. 2012; Bachelot et al. 2014; National Cancer Institute 2013; Yardley et al. 2013).
KT designed the study and collected the data. SN designed the study, conducted the analyses, and mainly wrote the manuscript. Both authors read and approved the final manuscript.
SN received funding from Novartis (Thailand) Limited to conduct a research project, but the project was terminated after the proposal of the project was developed.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Bachelot T, McCool R, Duffy S, Glanville D, Varley K, Fleetwood K, Zhang J, Jerusalem G (2014) Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 143:125–133View ArticleGoogle Scholar
- Bank of Thailand (2014) Daily foreign exchange rates, Bangkok. http://www.bot.or.th/english/statistics/financialmarkets/exchange/_layouts/Application/ExchangeRate/ExchangeRate.aspx. Accessed 3 Jan 2015
- Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529View ArticleGoogle Scholar
- Chalkidou K, Marquez P, Dhillon PK, Teerawattananon T, Anothaisintawee T, Gadelha G, Sullivan R (2014) Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol 15(3):e119–e131. doi:10.1016/S1470-2045(13)70547-3 View ArticleGoogle Scholar
- Chuthapisith S, Permsapaya W, Warnnissorn M, Akewanlop C, Sirivatanauksorn V, PrasarttongOsorth P (2012) Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women. Asian Pac J Cancer Prev 13:459–462View ArticleGoogle Scholar
- de Bekker-Grob EW, Hol L, Donkers B, van Dam L, Habbema JD, van Leerdam ME, Kuipers EJ, Essink-Bot ML, Steyerberg EW (2010) Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Value Health 13(2):315–323View ArticleGoogle Scholar
- Dedes KJ, Wilkerson PM, Reis-Filho JS (2011) Immunohistochemistry and molecular biology of breast cancers: old and new prognostic factors. breast cancer, Breast cancer a heterogeneous disease entry. Springer, London, pp 119–148View ArticleGoogle Scholar
- Dhillon S (2013) Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs 73:475–485View ArticleGoogle Scholar
- Ferlay J, Soerjomataram I, Ervik M, Dikshit S, Eser C, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr. Accessed 23 Jan 2015.
- Johnson P, Bancroft T, Barron R, Legg J, Li X, Watson H, Naeim A, Watkins A, Marshall DA (2014) Discrete choice experiment to estimate breast cancer patients’ preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. Value Health 17:380–389View ArticleGoogle Scholar
- Krinsky I, Robb AL (1986) On approximating the statistical properties of elasticities. Rev econo stati 68:715–719View ArticleGoogle Scholar
- Lancsar E, Louviere J (2008) Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics 26(8):661–677View ArticleGoogle Scholar
- Ministry of Public Health, Drug and Medical Supply Information Center (2013). http://dmsic.moph.go.th. Accessed 15 Jun 2013.
- National Cancer Institute (2013) FDA approval for everolimus. http://www.cancer.gov/cancertopics/druginfo/fda-everolimus#Anchor-Breast. Accessed 13 Jan 2015.
- National Cancer Institute, Thailand (2011) Hospital-based cancer registry. Information Technology Division, Bangkok.Google Scholar
- Park S, Koo JS, Kim MS, Park JS, Lee JS, Lee SI, Kim SI, Park BW (2012) Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohostochemistry. Breast 21(1):50–57View ArticleGoogle Scholar
- Rose JM, Bliemer MC (2013) Sample size requirements for stated choice experiments. Transportation 40(5):1021–1041View ArticleGoogle Scholar
- Yardley DA, Noguchi S, Pritchard KI, Burris HA III, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870–884View ArticleGoogle Scholar